Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A phase iia study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

    Research output: Contribution to journalReviewResearchpeer-review

  2. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Meningioma-Brain Crosstalk: A Scoping Review

    Research output: Contribution to journalReviewResearchpeer-review

  4. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biomarkers of subclinical atherosclerosis in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Comparison of Cytokines in Skin Biopsies and Tape Strips from Adults with Atopic Dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Arginase 1-based immune modulatory vaccines induce anti-cancer immunity and synergize with anti-PD-1 checkpoint blockade

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. No immediate effect of regulatory reduction of chromium in leather among adult patients with chromium allergy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Antitumor activity of immune checkpoint blocking antibodies against programmed death 1 (PD-1) in basal cell carcinoma (BCC) has been described. IO103 is a peptide vaccine against the major PD-1 ligand PD-L1. A phase IIa study of vaccination with IO103 and Montanide adjuvant was conducted in patients with resectable BCC (NCT03714529). Vaccinations were given six times every 2 weeks (q2w), followed by three vaccines q4w in responders. Primary endpoints were clinical responses of target tumors, change in target tumor size and immune responses to the vaccine. Secondary endpoint was safety. One tumor per patient was designated target tumor and biopsied twice during the course of vaccination. Synchronous non-target BCCs were not biopsied during vaccinations. Ten patients were vaccinated (six patients received six vaccinations and four patients received nine vaccinations). A partial response (PR) was seen in two target tumors. Two complete responses (CR) and one PR were observed in eight non-target tumors in four patients. No tumors progressed. Related adverse events were grade 1 and reversible. Immune responses against IO103 were induced in blood samples from nine of ten and skin-infiltrating lymphocytes from five of the nine patients. The regressions seen in non-target tumors suggest that IO103 may be effective against a subtype of BCC.

Original languageEnglish
Article number911
JournalCancers
Volume13
Issue number4
Pages (from-to)1-15
Number of pages15
ISSN2072-6694
DOIs
Publication statusPublished - Feb 2021

    Research areas

  • Basal cell carcinoma, Clinical trial, Immunotherapy, PD-L1, Vaccine, clinical trial, vaccine, immunotherapy, basal cell carcinoma

ID: 65949228